EVIDENCE LIBRARY
Diazepam as an anxiety reference for two serotonin-receptor antagonists
A preclinical study found different profiles across anxiety-like and depression-like assays.
A preclinical study found different profiles across anxiety-like and depression-like assays.
The two candidates differed
HBK-14 and HBK-15 were evaluated with receptor binding, functional assays, and animal behavioral tests. Diazepam was an anxiolytic reference. HBK-14 showed the stronger anxiety-like profile in the authors’ comparisons, while HBK-15 showed the stronger antidepressant-like profile. Pharmacological results implicated serotonergic mechanisms.
These compounds were not demonstrated to be benzodiazepine-site modulators merely because diazepam was included as a standard.
Assay performance is not clinical interchangeability
A favorable response in an elevated maze or conflict test does not establish patient efficacy, absence of sedation, or a human dose equivalence. Different tasks and species can yield different rankings.
For interpretation, retain the receptor evidence and each behavioral endpoint separately. The paper supports further development of particular candidates, not replacement of benzodiazepine treatment or proof that the same subjective anxiety reduction occurred.
Source paper
Original analysis of the supplied journal article, identified as PMC4640659.